RxDoctor Payments Data

Megan Crookston

Physician Assistant · South Jordan, UTNPI 1659773216

Payments from drug & device makers

$2,021in general payments, 2019–2025

Across 104 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$532
  • Abbott$331
  • Lilly USA, LLC$239
  • Dexcom, Inc.$104
  • Boston Scientific$100
  • Novo Nordisk$90
  • plus $623 from 23 others

What the payments were for

  • Food & beverage$2,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,021 in reported general payments places this provider in the 80th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$21,372
Medicare patients
68
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$75,530
JardianceEmpagliflozin33$58,508
TrulicityDulaglutide14$21,244
Spiriva HandihalerTiotropium Bromide16$11,281
LinzessLinaclotide12$10,443
Breo ElliptaFluticasone/Vilanterol15$6,060
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,426
Theophylline ErTheophylline Anhydrous12$1,657
Atorvastatin Calcium141$1,606
Gabapentin49$1,544
Omeprazole85$1,529
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$1,403
Levothyroxine Sodium125$1,321
Bupropion XlBupropion Hcl49$1,295
Metformin Hcl ErMetformin Hcl63$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$90$75,53032 claims
Boehringer IngelheimJardiance$22$58,50833 claims
Lilly USA, LLCTrulicity$239$21,24414 claims
AbbVieLinzess$532$10,44312 claims
GSKBreo Ellipta$44$6,06015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in South Jordan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →